- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02536105
PK/PD Pediatric ADHD Classroom Study
Pharmacokinetic Pharmacodynamic Studies of Methylphenidate Extended Release Products in Pediatric Attention Deficit Hyperactivity Disorder
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
This is a randomized, double-blind, 4-treatment and 4-period crossover study conducted in a school laboratory environment to evaluate the hour-by-hour behavioral instrument scores and hour-by-hour PK of 3 different extended-release MPH formulations as well as placebo in children with ADHD. The complete study consists of three periods: Screening, Dose Titration and Double-Blind Crossover in a Laboratory Classroom.
The double-blind phase will consist of four periods (or four weeks): each week will consist of blinded administration with one of the three active methylphenidate hydrochloride treatments or placebo from Sunday through Saturday. On the last day of each period (Saturday), study participants will be evaluated in a laboratory classroom setting. On Saturdays, the blinded doses of each study drug will be administered at the school site by study staff on the morning of the test laboratory classroom day. On the other days, the medication will be taken in the morning at home.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02114
- Massachusetts General Hospital
-
-
Nevada
-
Las Vegas, Nevada, Forenede Stater, 89128
- Center for Psychiatry and Behavioral Medicine
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Male and female outpatients
- Ages 6-12 years at time of screening
- Judged by the investigator to be physically healthy and suitable for participation in the study
- Diagnosis of DSM-5ADHD combined, predominantly inattentive or hyperactive/impulsive presentation, per clinical evaluation and confirmed by the MINI-KID
- Clinical Global Impressions-Severity (CGI-S) ≥ 3
- ≥ 90th percentile normative value for gender and age on the ADHD RS-IV total score at screening or baseline
- Study participant has a parent/legal guardian who is willing and able to give written informed consent for him/her to participate in the study
- Study participant must be able to give assent to participate in the trial
- Study participant and legal guardian must be able to speak and understand English
- Able to tolerate multiple finger pricks
- Willing to comply with all study procedures
Exclusion Criteria:
- Current (last month) psychiatric diagnosis other than specific phobia, motor skills disorders, oppositional defiant disorder, sleep disorders, elimination disorders, adjustment disorders, learning disorders, or communication disorders. Participants with school phobia or separation anxiety will not be eligible
- Cognitively impaired, in the investigator's opinion
- Any clinically significant chronic medical condition that, in the judgment of the investigator, may interfere with the participant's ability to participate in the study
- Seizure disorder excluding a history of febrile seizures
- Thyroid disease
- Tourette's disorder or chronic tic disorder (mild medication induced tics are allowed)
- Serious cardiac condition including cardiomyopathy, serious arrhythmias, structural cardiac disorders, or severe hypertension
- Glaucoma
- Current or recent (within the past 6 months) DSM-5 drug dependence or substance abuse (excluding nicotine and caffeine)
- Pregnant or nursing females. Females must have a negative urine pregnancy test at screening as well as four additional visits and must be abstinent or use adequate and reliable contraception throughout the study
- Currently treated and satisfied with ADHD medication
- Current psychotropic medications other than sedative hypnotics for sleep
- Use of atomoxetine, clonidine, guanfacine or a monoamine oxidase inhibitor within 28 days of the baseline visit
- Participation in another investigational medication study within 30 days prior to screening
- Clinically significant abnormal laboratory result, electrocardiogram (ECG) result, physical examination, or vital signs at screening that the investigator considers to be inappropriate to allow participation in the study
- Planned use of prohibited drugs from the baseline visit through the end of the trial
- History of allergic reaction or a known or suspected sensitivity to any substance that is contained in the study drugs
- Food allergies that are determined by the PI as too severe to be easily accommodated for during the study
- Inability to swallow study medication
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: Methylphenidate HCl ER tablets 1
During the open-label optimization phase, one of the methylphenidate hydrochloride extended-release products will be titrated at weekly intervals of 18mg increments until an optimal dose is achieved or a maximum of 72mg per day is reached.
During the double-blind phase, participants will receive blinded treatment each week.
The dose of each methylphenidate hydrochloride extended-release product will be determined by the optimized dose during the open-label optimization phase
|
|
Placebo komparator: Placebo
During the double-blind period, in one of the 4 study weeks, the study participant will take a blinded placebo instead of one of the the 3 active comparators.
|
|
Aktiv komparator: Methylphenidate HCl ER tablets 2
During the open-label optimization phase, one of the methylphenidate hydrochloride extended-release products will be titrated at weekly intervals of 18mg increments until an optimal dose is achieved or a maximum of 72mg per day is reached.
During the double-blind phase, participants will receive blinded treatment each week.
The dose of each methylphenidate hydrochloride extended-release product will be determined by the optimized dose during the open-label optimization phase
|
|
Aktiv komparator: Methylphenidate HCl ER for suspension
During the open-label optimization phase, one of the methylphenidate hydrochloride extended-release products will be titrated at weekly intervals of 18mg increments until an optimal dose is achieved or a maximum of 72mg per day is reached.
During the double-blind phase, participants will receive blinded treatment each week.
The dose of each methylphenidate hydrochloride extended-release product will be determined by the optimized dose during the open-label optimization phase
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Permanent Product Measure of Performance (PERMP) for Three Methylphenidate Hydrochloride Extended-release Drug Products
Tidsramme: 0.5, 1.5, 2.5, 4, 5, 6, 8, 10 and 12 hours post-dose on each classroom day
|
The Permanent Product Measure of Performance (PERMP) involves objective individualized mathematics tests.
Scores will be obtained ten times on each classroom day at pre-dose, and at approximately 0.5, 1.5, 2.5, 4, 5, 6, 8, 10 and 12 hours post-dose.
PERMP Attempted is reported here.
Scale ranges 0 math questions answered to 400 math questions answered.
The more number of questions answered (better score), the higher the PERMP Attempted score is.
|
0.5, 1.5, 2.5, 4, 5, 6, 8, 10 and 12 hours post-dose on each classroom day
|
Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Rating Scale for Three Methylphenidate Hydrochloride Extended-release Drug Products
Tidsramme: 0.5, 1.5, 2.5, 4, 5, 6, 8, 10 and 12 hours post-dose on each classroom day
|
The Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) scale is a validated, 13-item rating of subjective impairment of classroom behaviors (0 = normal/no impairment; 1 = slight impairment; 2 = mild impairment; 3 = moderate impairment; 4 = severe impairment; 5 = very severe impairment; 6 = maximal impairment).
The SKAMP consists of four subscales: SKAMP-Attention, SKAMP-Deportment, SKAMP-Quality of Work, and SKAMP-Compliance, in addition to SKAMP-Total (reported here).
SKAMP-Total is a sum of the four sub-scales and has a range of 0-78.
The higher the score, the higher the impairment.
Scores will be obtained during each classroom cycle during each full laboratory classroom day at pre-dose, and at 0.5, 1.5, 2.5, 4, 5, 6, 8, 10, and 12 hours post-dose.
The scores will be based on the child's behavior during 20 minutes of each cycle.
|
0.5, 1.5, 2.5, 4, 5, 6, 8, 10 and 12 hours post-dose on each classroom day
|
Maximum Drug Concentration Observed (Cmax) for Three Methylphenidate Hydrochloride Extended-release Drug Products
Tidsramme: 0.5, 1.5, 2.5, 4, 5, 6, 8, and 12 hours post-dose on each classroom day
|
PK samples will be taken eight times on each classroom day at approximately 0.5, 1.5, 2.5, 4, 5, 6, 8, and 12 hours post-dose, and Cmax will be measured.
The objectives of this measure is to estimate PK metrics, including Cmax, appropriate for characterizing rate and extent of absorption in each phase of the drug release and the evaluate the disposition and eliminating processes for each medication studied.
The minimum value is pg/mL and there is was no maximum defined prior to the interventions.
|
0.5, 1.5, 2.5, 4, 5, 6, 8, and 12 hours post-dose on each classroom day
|
Time to Reach Cmax (Tmax) for Three Methylphenidate Hydrochloride Extended-release Drug Products
Tidsramme: 0.5, 1.5, 2.5, 4, 5, 6, 8, and 12 hours post-dose on each classroom day
|
PK samples will be taken eight times on each classroom day at approximately 0.5, 1.5, 2.5, 4, 5, 6, 8, and 12 hours post-dose, and Tmax will be measured
|
0.5, 1.5, 2.5, 4, 5, 6, 8, and 12 hours post-dose on each classroom day
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Psykiske lidelser
- Sygdomme i nervesystemet
- Neurologiske manifestationer
- Dyskinesier
- Opmærksomhedsunderskud og forstyrrende adfærdsforstyrrelser
- Neuroudviklingsforstyrrelser
- Attention Deficit Disorder med hyperaktivitet
- Hyperkinesi
- Lægemidlers fysiologiske virkninger
- Neurotransmittermidler
- Molekylære mekanismer for farmakologisk virkning
- Neurotransmitter optagelseshæmmere
- Membrantransportmodulatorer
- Dopaminmidler
- Dopaminoptagelseshæmmere
- Centralnervesystemets stimulanser
- Methylphenidat
Andre undersøgelses-id-numre
- 2015P001113
- 5U01FD005240 (U.S. FDA-tilskud/-kontrakt)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Attention Deficit Hyperactivity Disorder
-
Children's National Research InstituteRekrutteringADHD | Attention Deficit Hyperactivity Disorder | Attention-Deficit Hyperactivity Disorder | Attention Deficit Disorder | TILFØJE | ADHD Overvejende uopmærksom type | ADHD - kombineret type | ADHD, overvejende hyperaktiv - impulsiv | Attention-Deficit Disorder i ungdomsårene | Attention-Deficit Hyperactivity...Forenede Stater
-
Ornit CohenUkendtAttention Deficit Hyperactivity Disorder | Attention Deficit Disorder med hyperaktivitet | Attention Deficit Disorder | Attention Deficit Disorders med hyperaktivitet | Attention Deficit Hyperactivity DisordersIsrael
-
Purdue Pharma LPAfsluttetAttention Deficit/Hyperactivity DisorderForenede Stater
-
The Hospital for Sick ChildrenEhave; Ontario Brain InstituteAfsluttetAttention-deficit Hyperactivity DisorderCanada
-
National Taiwan University HospitalAfsluttetAttention-deficit/Hyperactivity Disorder
-
National Taiwan University HospitalNational Science Council, TaiwanUkendtAttention Deficit/Hyperactivity DisorderTaiwan
-
National Taiwan University HospitalAfsluttetAttention-deficit/Hyperactivity DisorderTaiwan
-
University of California, Los AngelesNational Institute of Mental Health (NIMH)RekrutteringAttention-Deficit Hyperactivity DisorderForenede Stater
-
Ironshore Pharmaceuticals and Development, IncAfsluttetAttention-Deficit Hyperactivity DisorderForenede Stater
-
Florida International UniversityAfsluttetAttention-deficit/Hyperactivity DisorderForenede Stater
Kliniske forsøg med Placebo
-
SamA Pharmaceutical Co., LtdUkendtAkut bronkitis | Akut øvre luftvejsinfektionKorea, Republikken
-
National Institute on Drug Abuse (NIDA)AfsluttetBrug af cannabisForenede Stater
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyAfsluttetMandlige forsøgspersoner med type II-diabetes (T2DM)Tyskland
-
Heptares Therapeutics LimitedAfsluttetFarmakokinetik | SikkerhedsproblemerDet Forenede Kongerige
-
Regado Biosciences, Inc.AfsluttetSund frivilligForenede Stater
-
Texas A&M UniversityNutraboltAfsluttetGlucose and Insulin Response
-
Longeveron Inc.AfsluttetHypoplastisk venstre hjerte syndromForenede Stater
-
ItalfarmacoAfsluttetBeckers muskeldystrofiHolland, Italien
-
Universidade Estadual de LondrinaConselho Nacional de Desenvolvimento Científico e Tecnológico; Coordination...AfsluttetSund og rask | Kropssammensætning